Biotech Values

[DewDiligence]

IDIX:

The cash burn should accelerate since more candidates are moving into trials.

Actually, only one new candidate will be moving into the clinic: IDX320. IDX184 and IDX375 were already in the clinic during 4Q09, and hence their clinical-trial expenses were included in the $13M cash burn during the quarter. Moreover, ViiV Healthcare (GSK) pays 100% of the cost of the IDX899 program.

In short, I don’t expect the quarterly cash burn to increase by much relative to the $13M during 4Q09.